메뉴 건너뛰기




Volumn 3, Issue 2, 2001, Pages 65-70

A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT HUMAN MONOCLONAL ANTIBODY VASCULOTROPIN ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

EID: 0035718890     PISSN: 10955100     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1411.2001.32007.x     Document Type: Article
Times cited : (69)

References (20)
  • 1
    • 0032881898 scopus 로고    scopus 로고
    • Role of vascular endothelial growth factor in the regulation of angiogenesis
    • (1999) Kidney Int. , vol.56 , pp. 794-814
    • Ferrara, N.1
  • 4
    • 0030939698 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells
    • (1997) J. Urol. , vol.157 , pp. 2329-2333
    • Ferrer, F.A.1    Miller, L.J.2    Andrawis, R.I.3
  • 6
    • 0032848409 scopus 로고    scopus 로고
    • Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
    • (1999) J. Urol. , vol.161 , pp. 960-963
    • Melynk, O.1    Simmerman, M.2    Kim, K.J.3
  • 7
    • 0031898292 scopus 로고    scopus 로고
    • Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
    • (1998) Prostate , vol.35 , pp. 1-10
    • Borgstrom, P.1    Bourdon, M.A.2    Hillan, K.J.3
  • 10
    • 0027197245 scopus 로고
    • Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
    • (1993) Nature , vol.362 , pp. 841-844
    • Kim, K.J.1    Li, B.2    Winer, J.3
  • 14
    • 8944220720 scopus 로고    scopus 로고
    • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized study with palliative end points
    • (1996) J. Clin. Oncol. , vol.14 , pp. 1756-1764
    • Tannock, I.1    Osoba, D.2    Stockler, M.3
  • 15
    • 0032784113 scopus 로고    scopus 로고
    • Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
    • (1999) J. Clin. Oncol. , vol.17 , pp. 2506-2513
    • Kantoff, P.1    Halabi, S.2    Conaway, M.3
  • 16
    • 0034128221 scopus 로고    scopus 로고
    • Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized Phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
    • (2000) J. Clin. Oncol. , vol.18 , pp. 1440-1450
    • Small, E.J.1    Meyer, M.2    Marshall, M.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.